Foley Hoag Advises Calithera Biosciences in Global License Agreement with TransTech Pharma

March 6, 2015

Foley Hoag LLP recently advised clinical-stage pharmaceutical company Calithera Biosciences, Inc. as it entered into a worldwide license agreement with TransTech Pharma, granting Calithera exclusive rights to research, develop and commercialize TransTech's portfolio of hexokinase II inhibitors. Hexokinase II is the first and rate-limiting enzyme in the pathway that enables cancer cells to convert glucose to energy and building blocks that feed cancer cell growth.

Headquartered in South San Francisco, Calithera focuses on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Under the terms of the license agreement, Calithera will obtain exclusive, global rights to TransTech's hexokinase II inhibitors for research, development and commercialization. TransTech will receive an up-front payment and be eligible to receive future development and commercialization milestones, as well as royalties on sales of approved products.

Foley Hoag attorneys Hemmie ChangDavid Halstead and Karen Tepichin advised Calithera on this agreement.

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and investment management fields, and in cross-border disputes. Our professionals  possess the skills  and experience to provide exceptional senior level service to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.